Fabhalta: payments to doctors
Payments that named Fabhalta as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $2.2M
- Providers
- 11,032
- Transactions
- 37,328
- Average per transaction
- $58
The per-transaction average — $58 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 11,032 providers the average total is $196, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Novartis | $2,146,896 | 99.2% |
| Novartis Pharma AG | $16,346 | 0.8% |